VKTX

VK2809

NASH

Phase 2

Exp Date

TBD

Amp Volatility Score

Catalyst Info & Data Links

TITLE: VK2809 in NASH

  • ClinicalTrial.gov (NCT04173065): A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH (VOYAGE)


WHAT IS THE CATALYST EVENT?

  • TBD


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • TBD


PRIOR DATA

 

PRESS RELEASES

COMPETITORS

  • Ocaliva - Intercept Pharmaceuticals

  • Elafibranor - Genfit

MARKET

  • ~20 percent of people with NAFLD have NASH (learn more)

MECHANISM OF ACTION/ RATIONALE

  • VK2809 belongs to a family of novel prodrugs which are cleaved in vivo to release potent thyromimetics. Selective activation of the TRß receptor in liver tissue is believed to favorably affect cholesterol and lipoprotein levels via multiple mechanisms (source). 

Updated by HC

#VKTX, #VK2809, #NASH, #Non_Alcoholic_SteatoHepatitis

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon